|
시장보고서
상품코드
2080346
의료기기 시장 : 제품별, 기술별, 사용 형태별, 용도별, 최종 사용자별, 유통 채널별 - 세계 시장 예측(2026-2032년)Medical Devices Market by Product, Technology, Mode of Use, Application, End User, Distribution Channel - Global Forecast 2026-2032 |
||||||
360iResearch
의료기기 시장은 2032년까지 연평균 복합 성장률(CAGR) 6.22%로 성장해 6,149억 1,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 4,029억 2,000만 달러 |
| 추정 연도(2026년) | 4,267억 4,000만 달러 |
| 예측 연도(2032년) | 6,149억 1,000만 달러 |
| CAGR(%) | 6.22% |
의료기기 산업은 영상진단, 체외진단, 수술 기구, 이식형 의료기기, 환자 모니터링 시스템, 디지털 테라퓨틱스, 커넥티드 케어 플랫폼 등 다양한 분야를 아우르며, 전 세계 의료 분야의 중요한 축을 이루고 있습니다. 세계보건기구(WHO)에 따르면, 이 부문에는 7,000개 이상의 일반적인 기기 그룹으로 분류되는 200만 유형 이상의 의료기기가 포함되어 있으며, 이는 예방, 진단, 치료, 재활, 장기 요양에 이르는 광범위한 임상적 및 상업적 적용 범위를 여실히 보여주고 있습니다.
수요는 고령화, 만성 질환 유병률 증가, 저침습 의료 모델, 조기 진단 및 재택 모니터링으로의 전환에 의해 형성되고 있습니다. WHO 자료에 따르면, 전 세계 사망 원인의 대부분은 비전염성 질환이 차지하고 있으며, 지속적인 질환 관리를 뒷받침할 진단, 모니터링 및 치료 기술에 대한 필요성이 더욱 커지고 있습니다. 동시에 제조업체들은 규제 당국의 모니터링 강화, 사이버 보안에 대한 기대, 상환에 대한 압박, 복잡한 공급망과 같은 과제에 직면해 있습니다. 경쟁 우위는 증거 창출, 품질 관리 체계, 사용 편의성, 상호 운용성, 그리고 규제 시장 전반에 걸쳐 책임감 있게 혁신을 확대해 나가는 능력에 점점 더 의존하고 있습니다.
의료기기 산업의 혁신적인 변화
의료기기 산업의 동향은 제품 중심의 제조에서 데이터를 활용한 성과 중심의 헬스케어 솔루션으로 전환되고 있습니다. 병원 및 의료 시스템에서는 시술 시간 단축, 진단 정확도 향상, 원격 환자 관리 지원, 전자 진료 기록과의 연동이 가능한 의료기기를 우선적으로 도입하고 있습니다. 이에 따라 커넥티드 모니터링, 로봇 보조 수술, 웨어러블 센서, 현장 진단, 의료기기용 소프트웨어의 도입이 가속화되고 있습니다.
의료기기에 대한 인공지능의 누적 영향
인공지능(AI)은 제품 설계 및 영상 진단부터 예측 유지보수, 임상 의사결정 지원, 시판 후 조사에 이르기까지 의료기기의 전체 밸류체인에 누적 영향을 미치고 있습니다. 미국 식품의약국(FDA)이 공개한 AI/머신러닝(ML) 지원 의료기기 목록은 급속히 확대되고 있으며, 방사선과, 순환기내과, 신경과, 소화기내과, 병리과가 가장 활발한 분야로 꼽히고 있습니다. 이는 복잡한 데이터를 보다 신속하고 일관성 있게 해석하고자 하는 임상 현장의 강력한 요구를 반영한 것입니다.
세계 의료기기 시장의 주요 지역별 동향
아시아태평양은 의료 인프라 확충, 방대한 환자 수, 현지 생산 능력, 의료 기술 혁신 강화를 위한 국가 전략에 힘입어 의료기기 성장 분야에서 가장 활기찬 지역 중 하나로 자리매김하고 있습니다. 중국, 인도, 일본, 호주, 한국에서는 디지털 헬스, 진단 기술, 병원의 현대화가 추진되고 있는 반면, 규제 체계는 품질 및 임상적 근거에 관한 요건을 강화하는 방향으로 지속적으로 발전하고 있습니다. 일본, 한국, 중국에서는 고령화가 진행되면서 만성 질환 관리, 정형외과용 임플란트, 심혈관용 의료기기, 진단 기술, 원격 모니터링에 대한 수요가 증가하고 있습니다. 한편, 인도와 동남아시아 국가들에서는 합리적인 가격, 현지 생산, 필수 의료 기술에 대한 보다 폭넓은 접근성이 우선시되고 있습니다.
의료기기 전략에 관한 당 그룹의 주요 인사이트
아세안(ASEAN)은 인도네시아, 태국, 베트남, 말레이시아, 싱가포르, 필리핀에서의 의료 서비스 확대에 힘입어, 수요의 중심지이자 제조 거점으로서 전략적 중요성을 높여가고 있습니다. 싱가포르는 의료 기술 분야의 본사 기능, 임상 연구, 규제 조율 측면에서 계속해서 지역적 역할을 수행하고 있으며, 아세안(ASEAN) 전체의 의료기기 규제 조화를 위해 기울인 노력이 장기적으로 시장 진입의 효율화를 뒷받침하고 있습니다. 아세안 전역 수요는 만성 질환 부담 증가, 민간 의료 네트워크의 확대, 공공 부문의 조달, 비용 대비 효과가 높은 진단, 영상 진단 및 환자 모니터링 솔루션에 대한 수요에 의해 형성되고 있습니다.
의료기기 시장 성장과 관련된 주요 국가의 동향
미국은 높은 의료 지출, 선진적인 병원 시스템, FDA 규제 분야의 리더십, 강력한 임상 연구 네트워크, 디지털 헬스 및 AI를 활용한 기술에 대한 적극적인 투자에 힘입어 여전히 가장 영향력 있는 의료기기 시장으로 자리매김하고 있습니다. 캐나다는 안전성, 품질, 의료 기술 평가, 공공 조달 규정을 중시하는 반면, 멕시코는 확립된 북미 무역 및 공급망 연계 체제 하에서 의료 수요와 니어쇼어 생산 양면 모두에서 중요한 시장으로 자리매김하고 있습니다. 브라질은 라틴아메리카 최대 규모의 의료 시스템을 갖추고 있으므로, 의료 규제 당국의 요건, 수입 규정, 공공 조달 절차, 가격 책정 동향을 신중하게 파악해야 합니다.
의료기기 산업의 리더를 위한 실천적 제안
업계 리더는 제품 출시 전에 제품 전략을 임상적 근거, 보험 급여 제도, 사이버 보안, 규제 요건과 조화시켜야 합니다. 규제 당국, 보험사, 임상의, 조달 팀, 환자와 조기에 협력함으로써 개발 위험을 줄이고 제품의 보급을 촉진할 수 있습니다. 또한, 제조업체는 설계 검증, 인체공학, 표시, 시판 후 계획이 실제 임상 워크플로우와 다양한 환자 집단을 반영하고 있는지 확인해야 합니다.
의료기기 분석을 위한 조사 기법
본 요약본은 검증된 공개 정보원, 규제 지침, 산업 표준 및 권위 있는 의료 데이터에 중점을 둔 체계적인 2차 조사 기법을 활용하여 작성되었습니다. 참조한 정보 출처에는 미국 FDA, 유럽연합 집행위원회, 세계보건기구(WHO), 각국의 보건·의료기기 규제 당국, 표준화 기관, 일반에 공개된 의료 정책, 임상 및 규제 관련 문서 등이 포함됩니다.
결론 : 의료기기의 미래를 만들어 가다.
의료기기 산업은 커넥티드 케어, AI를 활용한 워크플로우, 규제 강화, 임상적 가치에 대한 기대감 고조 등으로 특징지어지는 변혁이 가속화되는 시기에 접어들고 있습니다. 진단, 모니터링, 최소 침습 치료, 디지털 치료, 재택 간호 등 각 부문에서 여전히 큰 기회가 존재하지만, 성공을 위해서는 혁신, 근거, 규정 준수, 품질, 사이버 보안, 시장 접근에 걸친 체계적인 실행이 필수적입니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향(2026년)
제7장 의료기기 시장 : 제품별
제8장 의료기기 시장 : 기술별
제9장 의료기기 시장 : 사용 형태별
제10장 의료기기 시장 : 용도별
제11장 의료기기 시장 : 최종 사용자별
제12장 의료기기 시장 : 유통 채널별
제13장 의료기기 시장 : 지역별
제14장 의료기기 시장 : 그룹별
제15장 의료기기 시장 : 국가별
제16장 경쟁 구도
제17장 기업 개요
KTH 26.07.14The Medical Devices Market is projected to grow by USD 614.91 billion at a CAGR of 6.22% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 402.92 billion |
| Estimated Year [2026] | USD 426.74 billion |
| Forecast Year [2032] | USD 614.91 billion |
| CAGR (%) | 6.22% |
The medical devices industry is a critical pillar of global healthcare, spanning diagnostic imaging, in vitro diagnostics, surgical instruments, implantable devices, patient monitoring systems, digital therapeutics, and connected care platforms. According to the World Health Organization, the sector includes more than 2 million different kinds of medical devices organized into over 7,000 generic device groups, underscoring the breadth of clinical and commercial applications across prevention, diagnosis, treatment, rehabilitation, and long-term care.
Demand is being shaped by aging populations, rising chronic disease prevalence, minimally invasive care models, and the shift toward earlier diagnosis and home-based monitoring. WHO data show that noncommunicable diseases account for most global deaths, reinforcing the need for diagnostics, monitoring, and therapeutic technologies that support continuous disease management. At the same time, manufacturers face tighter regulatory scrutiny, cybersecurity expectations, reimbursement pressure, and complex supply chains. Competitive advantage increasingly depends on evidence generation, quality systems, usability, interoperability, and the ability to scale innovation responsibly across regulated markets.
Transformative Shifts in the Medical Devices Landscape
The medical devices landscape is shifting from product-centric manufacturing toward data-enabled, outcome-oriented healthcare solutions. Hospitals and health systems are prioritizing devices that reduce procedure time, improve diagnostic accuracy, support remote patient management, and integrate with electronic health records. This is accelerating adoption of connected monitoring, robotic-assisted procedures, wearable sensors, point-of-care diagnostics, and software as a medical device.
Regulation is also transforming the market. The European Union Medical Device Regulation and In Vitro Diagnostic Regulation have raised expectations for clinical evidence, post-market surveillance, and traceability. In the United States, FDA guidance on cybersecurity, real-world evidence, and artificial intelligence-enabled devices is influencing design controls and product life-cycle management. Global alignment with recognized standards, including ISO 13485 for quality management and IEC 62304 for medical device software life-cycle processes, is becoming increasingly important. As a result, successful device companies are aligning innovation strategy with compliance, reimbursement, and cybersecurity from the earliest development stages.
Cumulative Impact of Artificial Intelligence on Medical Devices
Artificial intelligence is creating a cumulative impact across the medical device value chain, from product design and imaging interpretation to predictive maintenance, clinical decision support, and post-market surveillance. The U.S. FDA's public list of AI/ML-enabled medical devices has expanded rapidly, with radiology, cardiology, neurology, gastroenterology, and pathology among the most active categories, reflecting strong clinical demand for faster and more consistent interpretation of complex data.
AI also changes the operating model for manufacturers. Algorithms require representative training data, bias assessment, cybersecurity controls, continuous performance monitoring, and transparent change-management processes. Regulators are increasingly emphasizing good machine learning practice, predetermined change control plans, human factors, and real-world performance monitoring. For industry leaders, the opportunity is not only to add AI features, but to build trusted, validated, and clinically useful systems that support clinicians while meeting regulatory expectations for safety, effectiveness, explainability, and post-deployment monitoring.
Key Regional Insights Across Global Medical Devices
Asia-Pacific is one of the most dynamic regions for medical device growth, supported by expanding healthcare infrastructure, large patient populations, local manufacturing capacity, and national strategies to strengthen medtech innovation. China, India, Japan, Australia, and South Korea are advancing digital health, diagnostics, and hospital modernization, while regulatory pathways continue to evolve toward stronger quality and clinical evidence requirements. Aging populations in Japan, South Korea, and China are increasing demand for chronic disease management, orthopedic implants, cardiovascular devices, diagnostics, and remote monitoring, while India and Southeast Asian economies are prioritizing affordability, local production, and broader access to essential medical technologies.
North America remains a global benchmark for innovation, commercialization, and regulatory science, led by the United States and supported by Canada's established healthcare system and device oversight. Latin America, with Brazil and Mexico as important anchors, is seeing demand for cost-effective diagnostics, imaging, and hospital equipment as public and private providers expand access and modernize care delivery. Europe remains a highly regulated and mature market where EU MDR and IVDR compliance, clinical evidence, notified body capacity, and sustainability requirements are reshaping portfolios. The Middle East is investing in hospital infrastructure, specialty care, and digital health, particularly across Gulf economies, while Africa's medical device opportunities are closely tied to access, affordability, diagnostics, workforce capacity, maintenance capabilities, and resilient supply chains.
Key Group Insights for Medical Device Strategy
ASEAN is gaining strategic relevance as both a demand center and manufacturing base, supported by healthcare expansion in Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines. Singapore continues to play a regional role in medtech headquarters, clinical research, and regulatory coordination, while broader ASEAN medical device harmonization efforts support market access efficiency over time. Demand across ASEAN is being shaped by rising chronic disease burdens, expanding private healthcare networks, public-sector procurement, and the need for cost-effective diagnostics, imaging, and patient monitoring solutions.
The GCC is investing heavily in advanced hospitals, specialty care, and digital transformation, creating demand for imaging, surgical, monitoring, and connected care technologies. The European Union is defined by rigorous compliance under MDR and IVDR, making clinical evidence, post-market surveillance, unique device identification, and notified body capacity critical commercial factors. BRICS economies offer scale and localization opportunities, but require country-specific regulatory, pricing, procurement, and manufacturing strategies. G7 markets continue to set high standards for innovation, reimbursement, health technology assessment, cybersecurity, and quality, while NATO-aligned countries emphasize supply resilience, cyber protection, and continuity of critical healthcare infrastructure, particularly for essential devices and digital health systems.
Key Country Insights for Medical Device Growth
The United States remains the most influential medical device market, driven by high healthcare spending, advanced hospital systems, FDA regulatory leadership, strong clinical research networks, and active investment in digital health and AI-enabled technologies. Canada emphasizes safety, quality, health technology assessment, and public procurement discipline, while Mexico is important for both healthcare demand and nearshore manufacturing under established North American trade and supply chain links. Brazil is Latin America's largest healthcare system and requires careful navigation of health regulator requirements, import rules, public procurement processes, and pricing dynamics.
In Europe, the United Kingdom continues to refine its post-Brexit medical device framework, including transition arrangements and domestic conformity assessment, while Germany, France, Italy, and Spain are major markets shaped by hospital purchasing, reimbursement, clinical evidence requirements, and EU regulatory compliance. Russia presents a more complex operating environment due to sanctions, localization, import substitution policies, and procurement constraints. In Asia-Pacific, China combines scale with localization policies, volume-based procurement, and fast innovation; India is expanding domestic medtech production, public health access, and regulatory modernization; Japan prioritizes quality, reimbursement discipline, and aging-related technologies; Australia maintains a mature regulatory environment aligned with international standards; and South Korea is a strong hub for diagnostics, digital health, imaging, and advanced medical technology supported by export-oriented manufacturing and sophisticated healthcare infrastructure.
Actionable Recommendations for Medical Device Leaders
Industry leaders should align product strategy with clinical evidence, reimbursement, cybersecurity, and regulatory requirements before launch. Early engagement with regulators, payers, clinicians, procurement teams, and patients can reduce development risk and improve adoption. Manufacturers should also ensure that design validation, human factors engineering, labeling, and post-market plans reflect real clinical workflows and diverse patient populations.
Companies should prioritize interoperable and secure device architectures, build robust post-market surveillance systems, and invest in real-world evidence generation. Supply chain resilience should be strengthened through dual sourcing, regional manufacturing options, supplier qualification, inventory visibility, and quality oversight of critical components. For AI-enabled devices, leaders should implement governance for data quality, algorithm performance monitoring, bias mitigation, model documentation, cybersecurity, and controlled updates. Commercial teams should tailor market access strategies by region, considering reimbursement pathways, local clinical evidence expectations, tender systems, and service support requirements.
Research Methodology for Medical Devices Analysis
This executive summary is developed using a structured secondary research methodology focused on verified public sources, regulatory guidance, industry standards, and authoritative healthcare data. Sources considered include agencies such as the U.S. FDA, European Commission, World Health Organization, national health and device regulators, standards organizations, and publicly available healthcare policy, clinical, and regulatory documents.
The analysis applies triangulation across regulatory developments, technology adoption trends, regional healthcare priorities, disease burden indicators, digital health policy, and commercial dynamics. Insights are validated for relevance to medical device manufacturers, suppliers, investors, distributors, and healthcare providers, with emphasis on evidence-backed trends rather than speculative assumptions. The methodology excludes market estimation, market sizing, market share calculations, and market forecasting to maintain focus on verifiable industry drivers and strategic implications.
Conclusion: Building the Future of Medical Devices
The medical devices industry is entering a period of accelerated transformation defined by connected care, AI-enabled workflows, stronger regulation, and rising expectations for clinical value. Opportunities remain substantial across diagnostics, monitoring, minimally invasive treatment, digital therapeutics, and home-based care, but success depends on disciplined execution across innovation, evidence, compliance, quality, cybersecurity, and market access.
Organizations that combine engineering excellence with regulatory readiness, cybersecurity resilience, interoperable design, and data-driven clinical outcomes will be best positioned to compete. As healthcare systems seek safer, more efficient, and more accessible care, medical device leaders must deliver technologies that are not only innovative, but trusted, serviceable, interoperable, and measurable in real-world performance.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Medical Devices Market, by Product
- 7.1. Diagnostic Devices
- 7.1.1. Imaging Devices
- 7.1.1.1. Computed Tomography (CT)
- 7.1.1.2. Magnetic Resonance Imaging (MRI)
- 7.1.1.3. PET Scanners
- 7.1.1.4. Ultrasound
- 7.1.1.5. X-ray
- 7.1.2. In Vitro Diagnostics (IVD)
- 7.1.2.1. Clinical Chemistry
- 7.1.2.2. Hematology
- 7.1.2.3. Immunoassay
- 7.1.2.4. Microbiology
- 7.1.2.5. Molecular Diagnostics
- 7.1.1. Imaging Devices
- 7.2. Medical Implants
- 7.2.1. Cardiovascular Implants
- 7.2.2. Dental Implants
- 7.2.3. Neurostimulators
- 7.2.4. Orthopedic Implants
- 7.3. Monitoring Devices
- 7.3.1. Blood Pressure Monitors
- 7.3.2. Cardiac Monitoring Devices
- 7.3.3. Fetal Monitors
- 7.3.4. Glucose Monitors
- 7.3.5. Patient Monitoring Systems
- 7.4. Surgical Devices
- 7.4.1. Electrosurgical Devices
- 7.4.2. Endoscopic Devices
- 7.4.3. General Surgical Instruments
- 7.4.4. Robotic Surgery Systems
- 7.4.5. Surgical Staplers
- 7.4.6. Sutures & Mesh
- 7.5. Therapeutic Devices
- 7.5.1. Defibrillators
- 7.5.2. Dialysis Equipment
- 7.5.3. Electrotherapy Devices
- 7.5.4. Infusion Pumps
- 7.5.5. Radiotherapy Equipment
- 7.5.6. Respiratory Therapy Devices
8. Medical Devices Market, by Technology
- 8.1. 3D-Printed Devices
- 8.2. AI-based Devices
- 8.3. Digital & Connected Devices
- 8.4. Laser-Based Devices
- 8.5. Nanotechnology-based Devices
- 8.6. Robotic Devices
- 8.7. Traditional Non-Digital Devices
9. Medical Devices Market, by Mode of Use
- 9.1. Reusable Medical Devices
- 9.2. Single-Use / Disposable Medical Devices
10. Medical Devices Market, by Application
- 10.1. Cardiology
- 10.2. Dentistry
- 10.3. Dermatology
- 10.4. ENT
- 10.5. Gastroenterology
- 10.6. General Surgery
- 10.7. Gynecology
- 10.8. Neurology
- 10.9. Oncology
- 10.10. Ophthalmology
- 10.11. Orthopedics
- 10.12. Pulmonology
- 10.13. Urology
11. Medical Devices Market, by End User
- 11.1. Academic & Research Institutes
- 11.2. Ambulatory Surgical Centers
- 11.3. Diagnostic Centers
- 11.4. Hospitals & Clinics
- 11.5. Long-Term Care Facilities
12. Medical Devices Market, by Distribution Channel
- 12.1. Offline
- 12.2. Online
13. Medical Devices Market, by Region
- 13.1. Asia-Pacific
- 13.2. North America
- 13.3. Latin America
- 13.4. Europe
- 13.5. Middle East
- 13.6. Africa
14. Medical Devices Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
15. Medical Devices Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
16. Competitive Landscape
- 16.1. Market Concentration Analysis, 2025
- 16.1.1. Concentration Ratio (CR)
- 16.1.2. Herfindahl Hirschman Index (HHI)
- 16.2. Recent Developments & Impact Analysis, 2025
- 16.3. Product Portfolio Analysis, 2025
- 16.4. Benchmarking Analysis, 2025
17. Company Profiles
- 17.1. 3M Company
- 17.2. Abbott Laboratories
- 17.3. Agappe Diagnostics Ltd.
- 17.4. Alcon Inc.
- 17.5. Align Technology, Inc.
- 17.6. AliveCor, Inc.
- 17.7. ARKRAY, Inc.
- 17.8. B. Braun Melsungen SE
- 17.9. Baxter International Inc.
- 17.10. Becton, Dickinson, and Company
- 17.11. BioSerenity Medical Devices Group
- 17.12. Boston Scientific Corporation
- 17.13. Canon Medical Systems Corporation
- 17.14. Cardinal Health, Inc.
- 17.15. CMR Surgical Ltd.
- 17.16. Edwards Lifesciences Corporation
- 17.17. Eko Health Inc.
- 17.18. Fresenius Medical Care AG
- 17.19. FUJIFILM Healthcare Americas Corporation
- 17.20. GE Healthcare Technologies Inc.
- 17.21. Healthy.io Ltd
- 17.22. Intuitive Surgical, Inc.
- 17.23. Johnson & Johnson
- 17.24. Masimo Corporation
- 17.25. Medtronic plc
- 17.26. Olympus Corporation
- 17.27. ResMed Inc.
- 17.28. Siemens Healthineers AG
- 17.29. Smith & Nephew plc
- 17.30. Sonova Holding AG
- 17.31. Stryker Corporation
- 17.32. Terumo Corporation
- 17.33. Zimmer Biomet Holdings, Inc.
